Sign in
UT

UFP TECHNOLOGIES INC (UFPT)·Q2 2025 Earnings Summary

Executive Summary

  • UFPT delivered another record quarter: revenue rose 37% YoY to $151.2M and adjusted EPS increased 27% to $2.50, with gross margin at 28.8% despite AJR labor inefficiencies .
  • Results vs consensus: Adjusted/“Primary” EPS beat ($2.50 vs $2.105*) while revenue was essentially in line/slightly below ($151.2M vs $151.6M*). The shortfall was tied to ~$5M of backlog not completed due to AJR staffing/training constraints; management expects Q3 to be the trough in efficiency .
  • Mix: MedTech sales +46% YoY to $139.3M; non‑medical –19.8% to $11.8M as the company prioritizes higher-growth MedTech .
  • Near-term outlook: Management flagged Q3 headwinds from AJR labor inefficiencies (~$7M revenue and ~$2.5M operating income impact modeled) with a rebound in Q4 as efficiencies normalize; tariffs remain manageable and largely pass‑through .
  • Strategic progress: Two tuck-ins (UNIPEC and TPI) add thin‑film and thermoplastic molding capabilities; both expected to be first-year accretive, supporting long-term MedTech growth, including robotic-assisted surgery pipeline expansion .

What Went Well and What Went Wrong

What Went Well

  • Strong topline and profitability: Sales +37% YoY to $151.2M; adjusted operating income +34.8% to $27.3M; adjusted EPS +27% to $2.50 .
  • MedTech growth momentum: Medical sales +46% to $139.3M driven by patient surfaces/support, interventional & surgical, and wound care (each >48% growth), with robotic-assisted surgery up 7% and large accounts growing; CEO: “Sales grew 37%… MedTech grew 46%” .
  • Cash generation and de‑leveraging: Q2 cash from operations $25.3M; ~$19M debt paydown; leverage well below 1.5x . Quote: “During our second quarter, we generated $25.3 million in cash from operations… ended the quarter with a leverage ratio well below 1.5 times.”

What Went Wrong

  • AJR labor disruption impacted margins and shipments: ~$1.2M margin impact in Q2; ~$5M of backlog pushed; management models greater impact in Q3 before improving in Q4 .
  • Gross margin compression YoY: Q2 gross margin 28.8% vs 30.0% a year ago; management attributed pressure primarily to AJR labor inefficiencies .
  • Advanced Components (non‑medical) weakness: Non‑medical sales –19.8% to $11.8M; management continues to allocate resources toward MedTech, anticipating some H2 improvement in aerospace/defense .

Financial Results

Headline Metrics (GAAP and Non-GAAP)

MetricQ2 2024Q1 2025Q2 2025
Revenue ($USD Millions)$110.177 $148.148 $151.176
GAAP Diluted EPS ($)$1.75 $2.21 $2.21
Adjusted EPS ($)$1.97 $2.47 $2.50
Gross Margin (%)30.0% 28.5% 28.8%
Operating Income ($M)$17.951 $23.126 $24.329
Adjusted Operating Income ($M)$20.229 $25.813 $27.275
Adjusted EBITDA ($M)$23.897 $30.236 $31.836

Consensus vs Actual (S&P Global; Primary EPS reflects adjusted EPS)

MetricQ1 2025 ConsensusQ1 2025 ActualQ2 2025 ConsensusQ2 2025 Actual
Revenue ($USD Millions)$139.934*$148.148 $151.554*$151.176
Primary EPS ($)$1.8825*$2.47 $2.105*$2.50
Primary EPS - # of Estimates4*—4*—
Revenue - # of Estimates4*—4*—

Values marked with * are retrieved from S&P Global.

Segment/End-Market Mix

MetricQ2 2024Q2 2025
Medical Sales ($USD Millions)—$139.3
Medical Sales YoY Growth (%)—46.0%
Non‑Medical Sales ($USD Millions)—$11.8
Non‑Medical Sales YoY Growth (%)—–19.8%

Cash Flow & Balance Sheet KPIs

KPIQ1 2025Q2 2025
Cash from Operations ($M)$13.8 $25.3
Debt Paydown in Quarter ($M)~$7 ~$19
Leverage Ratio<1.5x Well below 1.5x
Capex ($M)$2.8 $2.9

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue impact from AJR labor inefficiencyQ3 2025None providedModel approx –$7M revenue impact in Q3 New commentary
Operating income impact from AJR inefficiencyQ3 2025None providedModel approx –$2.5M operating income impact in Q3 New commentary
Gross Margin (%)Q3 2025None providedExpect lower than Q2; “low‑28s” modeled New commentary
Gross Margin (%)Q4 2025None providedRebound expected as labor efficiencies normalize New commentary
Effective Tax RateFY 2025Normalized 21%–23% (Q1 commentary) Q2 effective rate 20.6% (favorable DR mix) Maintained normalized range; Q2 below
AJR product transfer to DRQ4 2025 – early 2026None providedTransition ramps in Q4 2025; meaningful revenue in 2026 New timeline
Tariffs2025Not material (Q1) Q2 direct tariffs ~$150k (passed through); estimate ~$9M annual raw-material inflation impact, largely passed through Maintained view; quantified

No formal numerical revenue/EPS guidance was issued; management instead provided modeling parameters and qualitative outlook .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024 and Q1 2025)Current Period (Q2 2025)Trend
Robotic-assisted surgery pipelineTwo major programs slated for H2’25 launch; diversified relationships with top customers 7 customers in manufacturing; ~12 in development; largest customer grew ~10% sequentially; share around ~two‑thirds on drapes maintained Positive long-term; modest 2025 growth; broader customer base
AJR labor/operationsQ1 noted onboarding inefficiency at AJR affecting Q2; DR transfer planned; exclusive SPH contract to 2030 Q2 hit ~$1.2M margin; ~$5M backlog slip; model bigger Q3 hit, then Q4 improvement; DR transfers start Q4 Near-term headwind; abating into Q4
Tariffs/MacroQ1: limited direct exposure; pass-through expected Q2: ~$150k direct tariffs; ~$9M annual raw-material inflation impact largely passed through Manageable
DR footprint expansionOngoing expansion in La Romana; fifth building; programs launching H2’25 Santiago expansion for SPH; La Romana 5th building with R&D; equipment in place; hiring/training underway Execution progressing
M&A strategyFocus on injection molding capabilities; active pipeline Closed UNIPEC (specialty thin film) and TPI (injection molding PR); both expected accretive; continued funnel in molding Building capabilities; disciplined approach

Management Commentary

  • CEO on growth drivers: “Sales grew 37%, driven by strong contributions from our 2024 acquisitions combined with 5% organic growth. Our MedTech business grew 46%… Gross margins were 28.8% despite… approximately $1.2 million in incremental labor costs at our AJR facility.”
  • On AJR and remediation: “We believe Q3 will be the low point of that inefficiency with an estimated impact of approximately $2,500,000; Q4’s impact should be much smaller.”
  • On customer concentration risk/opportunity: “We feel like we have excellent relationships with these two customers… we don’t see the concentration as exposure; we see the relationship as opportunity.”
  • CFO on financial posture: “Adjusted operating margin for the second quarter was 18% of sales… we generated $25.3 million in cash from operations, paid down approximately $19 million in debt and ended the quarter with a leverage ratio well below 1.5 times.”

Q&A Highlights

  • Robotic surgery breadth: 7 manufacturing customers and ~12 in development; meaningful revenue from top 4–5 over next 1–2 years; drape share steady at ~two‑thirds this year .
  • AJR/DR transfer: Biggest inefficiency in Q3; DR transfer ramps in Q4 with revenue impact more visible into 2026 .
  • Margins: Q3 gross margins to dip (low‑28s modeled) due to AJR; rebound in Q4; tariffs not a material standalone margin driver .
  • Tariffs pass‑through: ~$150k direct in Q2; ~$9M annual raw material inflation effect expected to be passed through to customers .
  • M&A focus: Targeting injection molding; TPI and UNIPEC accretive and strategically additive; disciplined deals pipeline .

Estimates Context

  • Q2 2025 vs S&P Global consensus: Adjusted/Primary EPS beat ($2.50 actual vs $2.105* est), revenue in line/slightly below ($151.176M actual vs $151.554M* est). Q1 2025 also beat both EPS and revenue ($2.47 vs $1.8825*; $148.148M vs $139.934M*) .
  • Implications: Given Q3 modeled revenue and operating income headwinds from AJR (~$7M and ~$2.5M), consensus may need to trim Q3 revenue and margin assumptions, with partial recovery penciled in for Q4 as labor efficiencies improve .

Values marked with * are retrieved from S&P Global.

Key Takeaways for Investors

  • Core MedTech momentum remains strong (medical +46% YoY) and should underpin medium-term growth while Advanced Components remains deprioritized .
  • Near-term setup skewed by AJR: expect Q3 to be the trough on revenue/margins (modeled ~$7M revenue and ~$2.5M operating income headwind), with improving run-rate into Q4 as training ramps .
  • Quality of beat: EPS beat was driven by operating leverage and cost control despite gross margin pressure; cash generation supported rapid de‑leveraging (well below 1.5x), creating optionality for further M&A .
  • Strategic M&A is capability-driven (thin films, injection molding) and accretive, likely enhancing content per device and vertical integration—supporting margins and customer stickiness .
  • Robotic-assisted surgery remains a multi‑year growth engine with diversified platforms/customers and stable share at the largest account; 2025 growth modest, but pipeline breadth suggests accelerating 2026+ .
  • Tariffs manageable: direct costs are small and largely passed through; raw material inflation pass-through should limit margin risk .
  • Trading lens: Watch Q3 print for confirmation of modeled headwinds and signs of backlog conversion; any upside on AJR normalization or robotic program ramps into Q4 could catalyze estimate revisions higher .